


70380
B4 (cont'd)

27. (Once Amended) A compound having the following formula:



- ✓ wherein R¹ is -CH₂OH;
- R² and R⁴ are each hydrogen;
- R³ is -CONR⁷R⁸;
- R⁷ is methyl; and
- R⁸ is hydrogen.

REMARKS

Claims 1, 8-12, 20-24 and 26-27 are pending in this application. The application claims have been amended to clarify the scope of the Applicants' invention in response to the Examiner's § 112 rejections. These amendments have also reduced the number of compounds that fall within the scope of the claimed invention. These claim amendments are made without prejudice to Applicant's right to seek a patent on the cancelled subject matter by way of a continuing application.

The application Examples and claim 26 have been amended to replace the incorrect adenosine nomenclature introduced in Applicant's June 11, 2001 Reply with the proper adenosine nomenclature for the compounds of this invention identified in Examples 1-7. Claim 27 has been converted from a dependent claim into an independent claim in the Reply as well.

b

The specification and claim amendments described above do not add new matter to the application.

By way of review, the Applicants have discovered a new class of 2-adenosine N-Pyrazole compositions that are useful as adenosine receptor agonists and that are particularly useful as A_{2A} receptor agonists.

The Examiner's claim objections are overcome as discussed below.

I. Claims 26 and 28

The Examiner did not consider newly submitted claims 26 and 28 because they were deemed to be distinct in scope from the invention originally claimed.


Claim 26 has been amended to name each of the compounds synthesized in Examples 1-7 using adenosine nomenclature. Claim 28 has been cancelled from this application without prejudice. The compounds of claim 26 were originally presented in cancelled claim 19 using IUPAC nomenclature. Therefore the amendment to claim 26 does not add new matter to the application.

II. Adenosine Nomenclature

The Applicants acknowledge that the adenosine nomenclature added to the specification and claims in the June 11, 2001 Reply is incorrect. Examples 1-7 and claim 26 have been amended to incorporate the correct adenosine nomenclature for the compounds whose chemical structure and IUPAC name appear in those Examples and in original claim 19.

III. 1-18, 20-24 and 27 – 112, First Paragraph Rejection

The Examiner rejected claims 1-18, 20-24 and 27 under 35 U.S.C. § 112 ¶ 1 as containing subject matter which is not described in the specification. More specifically, it is the Examiner's position that claim 1 is directed to a vast array of compounds which are not all



enabled by the specification.

The Applicants disagree with the rejection of all pending claims under the first paragraph of Section 112. In order to facilitate an early allowance of at least some of the application claims, however, the Applicants have narrowed the scope of compounds falling within the scope of the claims to those compounds actually made in the Examples and closely related compounds. This amendment to the claims is made without prejudice to the Applicant's rights to seek a patent of the cancelled subject matter by way of a continuing application.

IV. The Section 112, Second Paragraph Rejection of Claims 1 and 23

The Examiner identified several problems with the nomenclature used in claims 1 and 23. The problematic language has either been cancelled from the claims by this amendment or the claims at issue have been amended in the manner suggested by the Examiner.


V. Claim 27

Claim 27 has been converted from a dependent claim to an independent claim in this Reply. Claim 27 is drawn to Compound 16 of application Example 5. Since the compound of claim 27 was synthesized by the Applicants, the Examiner's Section 112, first paragraph claim rejection does not apply to the claim and claim 27 is believed to be allowable.

In view of the amendments and arguments presented above, it is believed that pending claims 1, 8-12, 20-24 and 26-27 of this application are allowable and that all rejections and objections should be withdrawn. Favorable reconsideration and allowance of the application claims is, therefore, courteously solicited.

Dated: February 19, 2002

By


A Blair Hughes
Reg. No. 32,901
312-913-2123

